Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216484 | 0.84 | XDH (0.43) | XDHNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3274361 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2ENPP2AR | |
| SCHEMBL29821479 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2ENPP2AR | |
| SCHEMBL29951250 | 0.82 | ALDH1A1 (0.50) | XDHALDH1A1HPGDAR | |
| SCHEMBL12127975 | 0.81 | ALDH1A1 (0.56) | XDHALDH1A1HPGDAR | |
| SCHEMBL1331417 | 0.81 | XDH (0.52) | XDH | |
| SCHEMBL3589010 | 0.81 | XDH (0.47) | XDHNPC1RAB9AALDH1A1ENPP2 | |
| SCHEMBL5973009 | 0.78 | ENPP2 (0.53) | XDHNPC1RAB9AENPP2TP53 | |
| SCHEMBL15156401 | 0.78 | ENPP2 (0.52) | ENPP2 | |
| SCHEMBL12128121 | 0.78 | KDM4E (0.40) | XDHALDH1A1KDM4EUSP2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | XDH 1/4885NPC1 112/4885RAB9A 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.